GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thor Medical ASA (FRA:8NN) » Definitions » Return-on-Tangible-Asset

Thor Medical ASA (FRA:8NN) Return-on-Tangible-Asset : -69.54% (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Thor Medical ASA Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Thor Medical ASA's annualized Net Income for the quarter that ended in Dec. 2024 was €-4.97 Mil. Thor Medical ASA's average total tangible assets for the quarter that ended in Dec. 2024 was €7.15 Mil. Therefore, Thor Medical ASA's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2024 was -69.54%.

The historical rank and industry rank for Thor Medical ASA's Return-on-Tangible-Asset or its related term are showing as below:

FRA:8NN' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -153.2   Med: -50.69   Max: -26.09
Current: -59.35

During the past 13 years, Thor Medical ASA's highest Return-on-Tangible-Asset was -26.09%. The lowest was -153.20%. And the median was -50.69%.

FRA:8NN's Return-on-Tangible-Asset is ranked worse than
64.66% of 1494 companies
in the Biotechnology industry
Industry Median: -36.86 vs FRA:8NN: -59.35

Thor Medical ASA Return-on-Tangible-Asset Historical Data

The historical data trend for Thor Medical ASA's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thor Medical ASA Return-on-Tangible-Asset Chart

Thor Medical ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -97.06 -147.57 -149.78 -31.84 -47.24

Thor Medical ASA Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -107.71 -58.15 -0.39 -63.71 -69.54

Competitive Comparison of Thor Medical ASA's Return-on-Tangible-Asset

For the Biotechnology subindustry, Thor Medical ASA's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thor Medical ASA's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thor Medical ASA's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Thor Medical ASA's Return-on-Tangible-Asset falls into.


;
;

Thor Medical ASA Return-on-Tangible-Asset Calculation

Thor Medical ASA's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-3.592/( (4.03+11.179)/ 2 )
=-3.592/7.6045
=-47.24 %

Thor Medical ASA's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=-4.97/( (3.115+11.179)/ 2 )
=-4.97/7.147
=-69.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2024) net income data.


Thor Medical ASA  (FRA:8NN) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Thor Medical ASA Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Thor Medical ASA's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Thor Medical ASA Business Description

Traded in Other Exchanges
Address
Karenslyst Alle 9C, Oslo, NOR, 0278
Thor Medical ASA is a Norway-based biopharmaceutical company. The Company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. The Company has developed a proprietary technology for the manufacturing of radionuclides, alpha-particle emitters from natural resources. The high energy deposition and the short range of alpha particles make it possible to eradicate cancer cells while minimizing damage to nearby healthy cells.

Thor Medical ASA Headlines

No Headlines